Invasive Pneumococcal Disease in New Zealand, 2010
Invasive Pneumococcal Disease in New Zealand, 2010 Invasive Pneumococcal Disease in New Zealand, 2010
Trends in resistance to the non-β-lactam antibiotics for the last 10 years are shown inAppendix 12. All isolates remain susceptible to vancomycin. Moxifloxacin susceptibilityhas been tested since 2005, with no resistance identified and a maximum of one isolate perannum with intermediate resistance. Chloramphenicol resistance is uncommon and hasvaried between 1.2 and 3.4% over the last 10 years.Penicillin and cefotaxime resistance in each region and DHB is shown in Appendix 13.There were no significant differences in resistance between the four regions.Penicillin and cefotaxime resistance among isolates from the different age groups is shown inTable 11. There were no significant differences in resistance between the age groups.Table 11. Penicillin and cefotaxime resistance among isolates frominvasive pneumococcal disease cases by patient age, 2010Age group(years)Penicillinresistant 2MIC 0.12 mg/LNumber (% 1 ) isolatesintermediate 2MIC 1 mg/LCefotaximeresistant 2MIC 2 mg/L
Percent of penicillin-resistant isolates454035302520151050Figure 5. Serotype distribution among penicillin-resistant (meningitisinterpretation) pneumococci from invasive disease, 2001-20106B 9V 14 19F 23F 19A OtherSerotypeThe series of bars for each serotype represent the individual years 2001 to 2010 from left to right.Invasive pneumococcal disease 21 September 2011in NZ, 2010
- Page 1 and 2: INVASIVE PNEUMOCOCCAL DISEASEIN NEW
- Page 3 and 4: DISCLAIMERThis report or document (
- Page 5 and 6: CONTENTSSUMMARY ...................
- Page 7 and 8: SUMMARYA 4-dose schedule of the 7-v
- Page 9 and 10: 1. INTRODUCTIONPrior to 2009, the n
- Page 11 and 12: Data analyses were performed with S
- Page 13 and 14: 3. RESULTSIn 2010, 535 IPD cases we
- Page 15 and 16: The all-age rate of IPD in 2010 (12
- Page 17: 3.4 Disease incidence by ethnicityT
- Page 20 and 21: 3.7 Risk factors among IPD casesThe
- Page 23 and 24: 3.10 Serotype distributionTable 9.
- Page 25 and 26: Rate per 100 000The rate of disease
- Page 27: 3.11 Antimicrobial susceptibilityTa
- Page 31 and 32: type most frequently reported to ha
- Page 33 and 34: REFERENCES1 Green MJ, Cawley PFM. I
- Page 35 and 36: Appendix 1. Laboratory criteria upo
- Page 37 and 38: Appendix 3. Rates of invasive pneum
- Page 39 and 40: Appendix 5.2010Risk factors among i
- Page 41 and 42: Appendix 7. Serotypes among invasiv
- Page 43 and 44: Appendix 9. Serotype 1 invasive pne
- Page 45 and 46: Appendix 11. Trends in penicillin r
- Page 47 and 48: Appendix 13. Penicillin and cefotax
- Page 49: Appendix 15. Trends in penicillin r
Trends <strong>in</strong> resistance to the non-β-lactam antibiotics for the last 10 years are shown <strong>in</strong>Appendix 12. All isolates rema<strong>in</strong> susceptible to vancomyc<strong>in</strong>. Moxifloxac<strong>in</strong> susceptibilityhas been tested s<strong>in</strong>ce 2005, with no resistance identified and a maximum of one isolate perannum with <strong>in</strong>termediate resistance. Chloramphenicol resistance is uncommon and hasvaried between 1.2 and 3.4% over the last 10 years.Penicill<strong>in</strong> and cefotaxime resistance <strong>in</strong> each region and DHB is shown <strong>in</strong> Appendix 13.There were no significant differences <strong>in</strong> resistance between the four regions.Penicill<strong>in</strong> and cefotaxime resistance among isolates from the different age groups is shown <strong>in</strong>Table 11. There were no significant differences <strong>in</strong> resistance between the age groups.Table 11. Penicill<strong>in</strong> and cefotaxime resistance among isolates from<strong>in</strong>vasive pneumococcal disease cases by patient age, <strong>2010</strong>Age group(years)Penicill<strong>in</strong>resistant 2MIC 0.12 mg/LNumber (% 1 ) isolates<strong>in</strong>termediate 2MIC 1 mg/LCefotaximeresistant 2MIC 2 mg/L
Change language